Amundi Boosts Stock Holdings in ICU Medical, Inc. (NASDAQ:ICUI)

Amundi lifted its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 196.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,736 shares of the medical instruments supplier’s stock after buying an additional 8,436 shares during the period. Amundi owned approximately 0.05% of ICU Medical worth $2,050,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Edgestream Partners L.P. bought a new position in ICU Medical during the 4th quarter worth approximately $679,000. Jackson Creek Investment Advisors LLC bought a new position in shares of ICU Medical in the fourth quarter worth approximately $1,428,000. Raymond James Financial Inc. purchased a new position in shares of ICU Medical in the fourth quarter worth $10,003,000. Arizona State Retirement System raised its holdings in ICU Medical by 1.0% during the 4th quarter. Arizona State Retirement System now owns 6,730 shares of the medical instruments supplier’s stock valued at $1,044,000 after buying an additional 65 shares during the last quarter. Finally, Proficio Capital Partners LLC purchased a new stake in ICU Medical during the 4th quarter valued at $5,779,000. Institutional investors own 96.10% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on ICUI. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Tuesday. Jefferies Financial Group raised ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price target for the company in a research report on Wednesday, December 11th. Finally, Raymond James set a $97.00 price objective on ICU Medical in a research report on Wednesday, March 12th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $168.67.

ICU Medical Price Performance

Shares of NASDAQ ICUI opened at $149.21 on Tuesday. ICU Medical, Inc. has a 1 year low of $93.36 and a 1 year high of $196.26. The stock has a market capitalization of $3.66 billion, a P/E ratio of -32.65 and a beta of 0.73. The company’s 50-day moving average is $156.96 and its 200 day moving average is $164.86. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, CEO Vivek Jain sold 1,373 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $155.48, for a total transaction of $213,474.04. Following the completion of the transaction, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $16,262,119.64. This trade represents a 1.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 6.70% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.